This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Use of Cyclokapron for Treatment and Management of Women With Bleeding Disorders

This study has been completed.
Information provided by:
Mary M. Gooley Hemophilia Center Identifier:
First received: June 10, 2008
Last updated: September 18, 2008
Last verified: September 2008
The high percentage of failure using available non-surgical options to treat menorrhagia in women with bleeding disorders shows a continuing need for innovative treatments. This has led to development of this protocol in order to make available tranexamic acid as a potentially effective menorrhagia therapy option in women with an underlying bleeding disorder. We anticipate that Tranexamic Acid may be a beneficial choice for controlling menorrhagia in bleeding disorder patients.

Condition Intervention
vonWillebrand Disease Hemophilia Platelet Coagulation Disorders Drug: Cyclokapron

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Label Continuation Study for the Use of Cyclokapron for Treatment and Management of Women With Bleeding Disorders

Resource links provided by NLM:

Further study details as provided by Mary M. Gooley Hemophilia Center:

Primary Outcome Measures:
  • Reduced pictorial blood assessment chart scores from baseline [ Time Frame: 3 and 6 months after start of medication ]

Secondary Outcome Measures:
  • increased hematocrit [ Time Frame: 3 and 6 months from start of medication ]

Enrollment: 13
Study Start Date: April 2003
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TA
on treatment
Drug: Cyclokapron
(2) 500mg tablets taken by mouth every 6-8 hours
Other Name: tranexamic Acid

Detailed Description:
Women with heavy periods and with a diagnosed bleeding disorders are prescribed cyclokapron pills to be taken during their periods. Their periods are assessed at 3 and 6 months by filling out a pictorial blood assessment chart. If the drug appears to be working with no adverse effects the patients can continue to take the medication as long as it is available with follow up with the investigator every 6 months.

Ages Eligible for Study:   8 Years to 60 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • all menstruating women regardless of age
  • Women with heavy periods as measured by pictorial blood assessment chart
  • Women diagnosed with a bleeding disorder

Exclusion Criteria:

  • Acquired defective color vision
  • Factor VIII, Factor IX, FactorXI levels >250%
  • An inherited thrombophilic defect detected because of a positive family or personal history of thrombosis
  • Current use of oral contraceptives
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00697385

United States, New York
Mary M. Gooley Hemophilia Center
Rochester, New York, United States, 14621
Sponsors and Collaborators
Mary M. Gooley Hemophilia Center
Principal Investigator: Peter A Kouides, MD Mary M. Gooley Hemophilia Center
  More Information

Responsible Party: Peter A. kouides, M.D., Mary M. Gooley Hemophilia Center Identifier: NCT00697385     History of Changes
Other Study ID Numbers: 758-A-03-1
Study First Received: June 10, 2008
Last Updated: September 18, 2008

Additional relevant MeSH terms:
Blood Coagulation Disorders
Hemostatic Disorders
Von Willebrand Diseases
Pathologic Processes
Hematologic Diseases
Vascular Diseases
Cardiovascular Diseases
Hemorrhagic Disorders
Blood Coagulation Disorders, Inherited
Coagulation Protein Disorders
Blood Platelet Disorders
Genetic Diseases, Inborn
Tranexamic Acid
Antifibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Coagulants processed this record on September 21, 2017